Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Contributors:
      Erasmus University Medical Center Rotterdam (Erasmus MC); University of California San Diego (UC San Diego); University of California (UC); School of Medicine Univ California San Diego (UC San Diego); University of California (UC)-University of California (UC); Institut Pasteur Paris (IP); Emory University Atlanta, GA; Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf Hamburg (UKE); University of Liverpool; Harvard Medical School Boston (HMS); Massachusetts General Hospital Boston; Heinrich Pette Institute Hamburg; Università degli Studi di Roma "La Sapienza" = Sapienza University Rome (UNIROMA); University of California San Francisco (UC San Francisco); University College Dublin Dublin (UCD); Universität Bonn = University of Bonn; Chelsea and Westminster Hospital; IrsiCaixa (Institut de Recerca de la Sida); UNIROUEN - UFR Santé (UNIROUEN UFR Santé); Université de Rouen Normandie (UNIROUEN); Normandie Université (NU)-Normandie Université (NU); No funding source had involvement in this manuscript or thedecision to submit the manuscript for publication; All authors have provided equal contributions to the manuscript.
    • بيانات النشر:
      HAL CCSD
      Elsevier
    • الموضوع:
      2015
    • Collection:
      Normandie Université: HAL
    • نبذة مختصرة :
      International audience ; The Second European Round Table on the Future Management of HIV took place in Barcelona, 10-11 October 2014 and focused on the HIV-1 reservoir, strategies for HIV cure and primary HIV infection (PHI). Important issues in the HIV-1 reservoir research field are the validity of reservoir measurement techniques and the potential of new drugs to target latently infected cells. Current HIV-1 cure concepts are based on theoretical assumptions of biologically plausible mechanisms, supported by several clinical observations. Three main potential strategies are under investigation in order to achieve a sterilising cure or maintain HIV-1 remission: latency reversal resulting in antigen expression and viral cytolysis or immune targeted cell-death; immunological control of the reservoir; or replacement of the complete autologous haematopoietic and lymphoid stem-cell repertoire by transplantation. An interesting opportunity for restricting the size of the reservoir entails the early initiation of antiretroviral treatment (ART) during PHI. In terms of the reservoir, early treatment limits its size, alters its composition, and restricts the genetic variability of integrated proviral HIV-1 DNA. The challenges ahead involve the identification of patients undergoing seroconversion to HIV-1 and the prompt initiation of treatment. How the seemingly beneficial impact of early treatment will make cure more feasible, and whether the positive effects of the cure efforts outweigh the potentially negative impact of life-long ART, are important aspects of future collaborative research prospects.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/27482415; PUBMED: 27482415; PUBMEDCENTRAL: PMC4946744
    • الدخول الالكتروني :
      https://pasteur.hal.science/pasteur-01960781
      https://pasteur.hal.science/pasteur-01960781v1/document
      https://pasteur.hal.science/pasteur-01960781v1/file/jve-1-211.pdf
    • Rights:
      http://creativecommons.org/licenses/by-nc-nd/ ; info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.80E9E3C6